March 19 Mar 19
2019
Tuesday Tue
Event

3rd Annual Center for Definitive and Curative Medicine (CDCM) Symposium

Learn about new cell-based medicine discoveries, pre-clinical development and clinical trials of curative medicines and challenges in bringing these cures to market at this one-day conference for clinicians, basic scientists, patient advocates, translational investigators and biotech and pharmaceutical experts.

Location

Paul Berg Hall, Li Ka Shing Learning and Knowledge Center (LKSC), Stanford, California
291 Campus Drive
Stanford, CA 94305
USA

Loading Map...

Paul Berg Hall, Li Ka Shing Learning and Knowledge Center (LKSC), Stanford, California

291 Campus Drive
Stanford CA, 94305
Get Directions

Program

7:30-8:00am

Breakfast

 

8:00-8:10am 

Opening Remarks: Dean Lloyd Minor, School of Medicine, Paul King, President and CEO, Lucile Packard Children's Hospital and David Entwistle, President and CEO, Stanford Health Care 

8:10-8:15am

Welcome: Matthew Porteus, MD, PhD, Associate Director, CDCM

8:15-9:00am

 

Introduction of Keynote: Irving Weissman, MD, Director, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine

Opening Keynote: David Baltimore, PhD, President Emeritus, Robert Andrews Millikan Professor of Biology, California Institute of Technology

TITLE: “Therapy Enters the Genetic Era”

Session 1: New Cell-Based Medicine Discoveries                                                                                      

Moderator: Irving Weissman, MD

9:00-9:30am

Calvin Kuo, MD, PhD, Maureen Lyles D’Ambrogio Professor, Stanford University

TITLE: “Using organoids to model immune-mediated diseases”

9:30-10:00am 

Tom Wandless, PhD, Professor of Chemical and Systems Biology and, by courtesy, of Chemistry, Stanford University

TITLE: "Regulating Protein Stability with Ambitions for Cell Therapy"

10:00-10:30am

Kyle Loh, PhD, Assistant Professor of Developmental Biology (Stem Cell), Stanford University

TITLE: “A developmental roadmap to efficiently generate human tissue progenitors from pluripotent stem cells”

10:30-10:45am

BREAK

Session 2: Pre-Clinical Development of Curative Medicines                                                                       

Moderator: Mary Leonard, M.D., M.S.C.E.

10:45-11:15am

Robbie Majzner, MD, Instructor in the Division of Pediatric Hematology-Oncology, Stanford University

TITLE: “Adoptive immunotherapy for pediatric solid tumors”

11:15-11:45am 

Maria Grazia Roncarolo, MD, Director, CDCM/Rosa Bacchetta, MD, Associate Professor of Pediatrics-Stem Cell Transplantation, Stanford University

TITLE: "Regulatory T-cell therapy for genetic and acquired immune-mediated diseases"

11:45-12:15pm

Natalia Gomez-Ospina, PhD, MD, Assistant Professor, Pediatrics, Genetics, Stanford University

TITLE: “Genome-edited human hematopoietic stem cells correct neurometabolic disorders: Proof-of-concept and safety studies for Mucopolysaccharidosis type I and Gaucher disease.”

12:15-1:00pm

LUNCH

Session 3: Clinical Trials in Curative Medicines 

Moderator: Michele Calos, PhD  

1:00-1:30pm

Chaitan Khosla, PhD, Director, ChEM-H, Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering and Professor of Chemistry and, by courtesy, of Biochemistry

TITLE: “Bench-to-bedside Translation of Innovative Molecules at Stanford”

1:30-2:00pm 

Alice Bertaina, MD, PhD, Associate Professor of Pediatrics-Stem Cell Transplantation, Stanford University 

TITLE: “Alpha/beta T-cell depleted haploidentical stem cell transplantation: a new platform for adoptive immunotherapy”

2:00-2:30pm

John Day, MD, PhD, Professor, Neurology & Neurological Sciences Director, Stanford Neuromuscular Disorders Program, Stanford University

TITLE: “SMA – a prototype for neurodegenerative disorders”

2:30-2:45pm

BREAK

Session 4: Challenges in Development and Commercialization of Curative Medicines 

Moderator:  Bruce K. Burnett, PhD, RAC 

2:45-3:15pm

Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the FDA

TITLE: “Optimizing the Clinical Development of Advanced Therapy Medicinal Products”

3:15-3:45pm

Fraser Wright, PhD, Principal, Wright Biologics Consulting

TITLE: “Gene Therapy Product Development: Technology Strategies for Curative

Precision Medicines”

3:45-4:15pm 

Lynn Frohnmayer, Fanconi Anemia Research Fund

TITLE: "Making Something from Nothing: One Family's Journey"

 

 

4:15-5:00pm

Closing Keynote: David Chang, MD, PhD, President, Chief Executive Officer and Co-Founder, Allogene Therapeutics

TITLE:  "Shifting from Autologous to Allogeneic CAR T Therapy”

5:00-5:05pm

Closing Remarks: Maria Grazia Roncarolo, MD, Director, CDCM 

5:05-6:00pm

WINE & CHEESE RECEPTION

 


Event Sponsors

Maternal & Child Health Research Institute